z-logo
open-access-imgOpen Access
Inhibition of Experimental Autoimmune Encephalomyelitis in Human C-Reactive Protein Transgenic Mice Is FcRIIB Dependent
Author(s) -
Xianzhen Hu,
Tyler Wright,
Nicholas Jones,
Theresa N. Ramos,
Gregory A. Skibinski,
Mark A. McCrory,
Scott R. Barnum,
Alexander J. Szalai
Publication year - 2010
Publication title -
autoimmune diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.681
H-Index - 32
eISSN - 2090-0422
pISSN - 2090-0430
DOI - 10.4061/2011/484936
Subject(s) - experimental autoimmune encephalomyelitis , transgene , medicine , genetically modified mouse , encephalomyelitis , immunology , multiple sclerosis , computational biology , pharmacology , biochemistry , biology , gene
We showed earlier that experimental autoimmune encephalomyelitis (EAE) in human C-reactive protein (CRP) transgenic mice (CRPtg) has delayed onset and reduced severity compared to wild-type mice. Since human CRP is known to engage Fc receptors and Fc receptors are known to play a role in EAE in the mouse, we sought to determine if FcRI, FcRIIb, or FcRIII was needed to manifest human CRP-mediated protection of CRPtg. We report here that in CRPtg lacking either of the two activating receptors, FcRI and FcRIII, the beneficial effects of human CRP are still observed. In contrast, if CRPtg lack expression of the inhibitory receptor FcRIIB, then the beneficial effect of human CRP is abrogated. Also, subcutaneous administration of purified human CRP stalled progression of ongoing EAE in wild-type mice, but similar treatment failed to impede EAE progression in mice lacking FcRIIB. The results reveal that a CRP→FcRIIB axis is responsible for protection against EAE in the CRPtg model

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom